Patent · US Active

Factor VIII formulations

US11020459B2 · kind B2 · utility

9Cited by

120References

18Claims

0Family size

Assignees

Baxalta Incorporated · CH
UNIVERSITY OF CONNECTICUT · US

Inventors

Michael Pikal · Mansfield Center, US
Serguei Tchessalov · Andover, US
Erik Bjornson · West Hollywood, US
Feroz Jameel · Covina, US
Marc Besman · Seattle, US

Key dates

Filing date	Aug 21, 2019
Grant date	Jun 1, 2021
Priority date	—
Expiry date	Aug 21, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P7/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A Factor VIII (FVIII) composition formulated such that NaCl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized FVIII.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.